ReviewCurrent treatment options in gastroenterology2018
Endoscopic Treatments of GERD.
Review in Current treatment options in gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 15 citations in OpenAlex.
- Transoral Incisionless Fundoplication Leads to Esophageal Mucosa Healing in Responder Patients Followed up to 2 Years, as Documented by Esophageal Mean Nocturnal Baseline Impedance.Journal of neurogastroenterology and motility · 2024Article
- Endoscopic Advances in the Diagnosis and Management of Gastroesophageal Reflux Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Endoscopic Non-ablative Radiofrequency Treatment (Stretta) for Gastroesophageal Reflux Disease (GERD).Current gastroenterology reports · 2024Review
- New Perspectives in Endoscopic Treatment of Gastroesophageal Reflux Disease.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementPURPOSE OF REVIEW: Endoscopic therapies for gastroesophageal reflux disease (GERD) are minimally invasive techniques which fill the gap between the medical therapy with proton pump inhibitors (PPIs) and surgical fundoplication. The main endoscopic therapies currently available in the USA are transoral incisionless fundoplication (TIF) using EsophyX device or less commonly, Medigus Ultrasonic Surgical Endostapler, and radiofrequency energy delivery to lower esophageal sphincter using Stretta device. Our aim was to examine the available evidence for these therapies. RECENT
findingsConsistent evidence for subjective improvement is available for fundoplication using EsophyX and Stretta, but improvement in objective parameters for GERD is not seen or evaluated in all the studies. There is a reduction in long-term efficacy seen with TIF and also to a lesser extent with Stretta. Endoscopic therapies do not replace surgical fundoplication and therefore are useful in patients with breakthrough symptoms on PPI such as regurgitation or those reluctant to take long-term PPI. An ideal patient is one who has symptoms and objective evidence of GERD such as abnormal pH study or erosive esophagitis without any significant anatomic distortion such as a hiatal hernia. Since these are endoluminal procedures, they do not address the hiatal hernia reduction or repair of crural defect. Adequate training in the technique and careful patient selection are essential prior to embarking on these procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.